SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Alliance Pharmaceutical -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (346)5/5/1999 11:31:00 PM
From: Cacaito  Respond to of 548
 
Ima-Rx and Dupont prevail in some patent dispute with Molecular Biosystems regarding perflurocarbon technologies for ultrasound images.

Sonus is also in this market with Abbott? and ready to go in Europe,
still pending FDA for US marketing.

Kind of crowded ultrasound market.

Is ALLP well protected with patents? they claim so.

I will take this Ultrasound market out of the valuation model, or at least decrease it to a certain percent of the market (10% sounds reasonable for conservative valuation model).




To: Dr. John M. de Castro who wrote (346)5/5/1999 11:37:00 PM
From: Cacaito  Read Replies (1) | Respond to of 548
 
Polyheme is a human hemoglobin base blood substitute product with some studies in replacing acute blood loss.

ncbi.nlm.nih.gov

And Northfield's Polyheme is in phase III trial (recent news).

Another in the blood field is Hemosol (from animal hemoglobin?).

Baxter was the one who fail in phase III. It seems they are in the outlook to buy or partner somebody in same market.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News